Results presented by AstraZeneca from its phase 3 trial of Imfinzi in patients with high-risk, non-muscle invasive bladder cancer (NMIBC) suggest that the PD-L1 inhibitor measures up to Pfizer’s PD-1 candidate sasanlimab. More: ESMO: Results for AZ's Imfinzi in early
read moreWith the launch of its first direct-to-patient program, Genentech is joining the wave of drugmakers setting up direct-to-consumer sales of popular products at steep discounts for cash-paying patients. More: Genentech preps for flu season with DTC program offering discounted Xofluza
read more
Seven new technologies selected to help transform NHS care and speed up diagnosis More: AI tools to be trialled in next phase of MHRA’s Airlock programme Source: News
read moreA Keytruda-based regimen has shown a statistically significant overall survival benefit in all comers with platinum-resistant recurrent ovarian cancer regardless of their PD-L1 expression levels. More: Merck's Keytruda follows primary endpoint win in ovarian cancer study with OS triumph Source:
read moreAt the final analysis of the phase 3 Applause-IgAN trial, Novartis’ complement factor B inhibitor Fabhalta showed that it can slow kidney function decline and IgAN progression, the company said. Novartis plans to leverage the data for regulatory submissions next
read more
Designation supports phase 3 launch in watch-and-wait patients in 2026 More: FDA grants fast Track status to Enterome’s EO2463 for follicular lymphoma Source: News
read more© 1994 - 2026 B.M. Pharmaceuticals